Innodem Neurosciences closes US$6 million Series A financing round

19 January 2021

On January 19, 2021, Innodem Neurosciences announced that it had closed a Series A financing round led by Morningside Ventures to support the development and commercialization of its proprietary, patented, digital biomarking technology of neurodegenerative diseases.

Innodem, based in Montreal, has developed mobile digital biomarking technology of Multiple Sclerosis, Alzheimer's disease, Parkinson's disease and related disorders, Frontotemporal Dementia and related disorders and Cancer-Related Cognitive Impairment ("chemo brain"). This novel eye-tracking and cognition testing technology is embodied in a HIPAA/PIPEDA compliant system consisting of an intuitive tablet application (smartphone coming soon) connected to a cloud-based AI infrastructure. The app is made up of a series of tasks that are completed in minutes, where a user's eye movement is recorded in data sets called Eye Movement Biomarkers (EMBs) and Gaze Mapping Biomarkers (GMBs). 

Gowling WLG advised Innodem with respect to this financing round with a team that included Olivier Therrien (client relationship), Georgi Paskalev and Jean-François Vadeboncoeur.


NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.